Overview

Pemetrexed +/- Carboplatin as Second Line Treatment in NSCLC

Status:
Unknown status
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to compare time to progression between the combination pemetrexed-carboplatin and pemetrexed alone in previously treated patients with locally advanced or metastatic NSCLC.
Phase:
Phase 2
Details
Lead Sponsor:
Gruppo Oncologico Italiano di Ricerca Clinica
Treatments:
Carboplatin
Pemetrexed